DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Evogliptin is an investigational drug.
There have been 16 clinical trials for Evogliptin. The most recent clinical trial was a Phase 3 trial, which was initiated on April 12th 2019.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Dong-A ST Co., Ltd., Samsung Medical Center, and Eurofarma Laboratorios S.A.
There are five US patents protecting this investigational drug and ninety-six international patents.
Recent Clinical Trials for Evogliptin
|The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients||Dong-A ST Co., Ltd.||Phase 1|
|Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control||Dong-A ST Co., Ltd.||Phase 3|
|Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases||Dong-A ST Co., Ltd.||Phase 4|
Top disease conditions for Evogliptin
Top clinical trial sponsors for Evogliptin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Evogliptin||Start Trial||Composition containing a DPP-IV inhibitor for preventing or treating renal diseases||DONG-A ST Co., Ltd (Seoul, KR)||Start Trial|
|Evogliptin||Start Trial||DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity||Dong-A Pharm. Co., Ltd. (Seoul, KR)||Start Trial|
|Evogliptin||Start Trial||Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients||Dong-A Pharmaceutical Co. Ltd. (Seoul, KR)||Start Trial|
|Evogliptin||Start Trial||Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate||Dong-A Pharmaceutical. Co., Ltd (Seoul, KR)||Start Trial|
|Evogliptin||Start Trial||Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate||DONG-A PHARMACEUTICAL CO., LTD. (Seoul, KR)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Evogliptin||European Patent Office||3015106||2033-06-26||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|